- Home
- GUTS vs VNRX Comparison
GUTS vs VNRX Comparison
Compare GUTS & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- VNRX
- Stock Information
- Founded
- GUTS 2010
- VNRX N/A
- Country
- GUTS United States
- VNRX United States
- Employees
- GUTS N/A
- VNRX N/A
- Industry
- GUTS
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GUTS
- VNRX Health Care
- Exchange
- GUTS NYSE
- VNRX Nasdaq
- Market Cap
- GUTS 58.9M
- VNRX 58.6M
- IPO Year
- GUTS 2024
- VNRX N/A
- Fundamental
- Price
- GUTS $1.12
- VNRX $0.52
- Analyst Decision
- GUTS Buy
- VNRX Strong Buy
- Analyst Count
- GUTS 1
- VNRX 4
- Target Price
- GUTS $10.00
- VNRX $4.17
- AVG Volume (30 Days)
- GUTS 201.2K
- VNRX 119.1K
- Earning Date
- GUTS 03-03-2025
- VNRX 03-31-2025
- Dividend Yield
- GUTS N/A
- VNRX N/A
- EPS Growth
- GUTS N/A
- VNRX N/A
- EPS
- GUTS N/A
- VNRX N/A
- Revenue
- GUTS $93,000.00
- VNRX $1,285,827.00
- Revenue This Year
- GUTS N/A
- VNRX $71,446.31
- Revenue Next Year
- GUTS N/A
- VNRX N/A
- P/E Ratio
- GUTS N/A
- VNRX N/A
- Revenue Growth
- GUTS N/A
- VNRX 97.50
- 52 Week Low
- GUTS $1.16
- VNRX $0.43
- 52 Week High
- GUTS $7.89
- VNRX $1.02
- Technical
- Relative Strength Index (RSI)
- GUTS 35.75
- VNRX 48.38
- Support Level
- GUTS $1.19
- VNRX $0.51
- Resistance Level
- GUTS $1.32
- VNRX $0.61
- Average True Range (ATR)
- GUTS 0.09
- VNRX 0.04
- MACD
- GUTS 0.00
- VNRX 0.00
- Stochastic Oscillator
- GUTS 9.09
- VNRX 50.10
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.